PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results for its oral Irinotecan nanoparticle formulation for the treatment of advanced colorectal cancer at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009.
